[go: up one dir, main page]

AR126708A1 - Vacuna para el vph - Google Patents

Vacuna para el vph

Info

Publication number
AR126708A1
AR126708A1 ARP220102097A ARP220102097A AR126708A1 AR 126708 A1 AR126708 A1 AR 126708A1 AR P220102097 A ARP220102097 A AR P220102097A AR P220102097 A ARP220102097 A AR P220102097A AR 126708 A1 AR126708 A1 AR 126708A1
Authority
AR
Argentina
Prior art keywords
hpv
vlps
chitosan
type
composition
Prior art date
Application number
ARP220102097A
Other languages
English (en)
Inventor
Andrew Bett
John P Bilello
Pedro J Cejas
Amy S Espeseth
Tong Fu
- Strable Erica Leigh Ming
Colleen M Barr
Sara Zimmermann
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of AR126708A1 publication Critical patent/AR126708A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación proporciona, entre otras cosas, una composición de vacuna de dosis única que incluye un adyuvante de quitosano y partículas similivíricas del PVH (las VLP) de al menos un tipo del papilomavirus humano (PVH) seleccionado del grupo que consiste en los tipos del PVH: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73 y 82, en que la composición de vacuna de dosis única proporciona una respuesta de vacuna para el PVH potenciada o comparable en comparación con una vacuna de dosis múltiples similar formulada sin tal adyuvante de quitosano. Reivindicación 1: Una composición farmacéutica que comprende: partículas similivíricas (las VLP) de al menos un tipo del papilomavirus humano (PVH) seleccionado del grupo que consiste en los tipos del PVH: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 5 51, 52, 53, 55, 56, 58, 59, 66, 68, 69, 70, 73 y 82, un quitosano; y un transportador farmacéuticamente aceptable. Reivindicación 42: Una composición farmacéutica que comprende partículas similivíricas (las VLP) de al menos un tipo del papilomavirus humano (PVH), en donde el al menos un tipo del PVH se selecciona del grupo que consiste en los tipos del PVH: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73 y 82; y 0,1 mg a aproximadamente 50 mg de un quitosano, en donde las VLP de PVH comprenden proteína Ll del PVH recombinante o proteína L1 + L2 del PVH recombinante, en donde las VLP de PVH de cada uno de los al menos uno de los tipos del PVH están presentes en una concentración de aproximadamente 10 mg a aproximadamente 300 mg por 0,5 ml de la composición farmacéutica, y en donde la concentración total de VLP está entre 10 mg y 2000 mg por 0,5 ml de la composición farmacéutica. Reivindicación 75: Una composición de vacuna de dosis única que comprende: un quitosano, partículas similivíricas (las VLP) de al menos un tipo del papilomavirus humano (PVH) seleccionado del grupo que consiste en los tipos del PVH: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73 y 82, y un transportador farmacéuticamente aceptable; en donde la composición de vacuna de dosis única proporciona una respuesta inmunitaria anti-PVH elevada o comparable con respecto a dosis múltiples de la misma composición formulada sin un adyuvante de quitosano.
ARP220102097A 2021-08-06 2022-08-04 Vacuna para el vph AR126708A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163230426P 2021-08-06 2021-08-06

Publications (1)

Publication Number Publication Date
AR126708A1 true AR126708A1 (es) 2023-11-08

Family

ID=83193593

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102097A AR126708A1 (es) 2021-08-06 2022-08-04 Vacuna para el vph

Country Status (5)

Country Link
US (1) US20230048144A1 (es)
EP (1) EP4380615A1 (es)
AR (1) AR126708A1 (es)
TW (1) TW202313658A (es)
WO (1) WO2023014853A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025176145A1 (zh) * 2024-02-23 2025-08-28 北京康乐卫士生物技术股份有限公司 九价人乳头瘤病毒疫苗及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
AU4270196A (en) 1994-10-07 1996-05-02 Lutz Gissmann Papilloma virus-like particles, fusion proteins and process for producing the same
US5820870A (en) 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
CN100506999C (zh) 2003-03-24 2009-07-01 麦克公司 Hpv31l1在酵母中的优化表达
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
RU2373219C2 (ru) 2004-03-24 2009-11-20 Мерк энд Ко. Инк. Оптимизированная экспрессия hpv 52 l1 в дрожжах
MX2007013472A (es) 2005-04-26 2008-04-02 Glaxosmithkline Biolog Sa Vacuna.
US10463608B2 (en) * 2008-09-29 2019-11-05 The Corporation Of Mercer University Microneedle-based transdermal delivery system and method of making same
CN105597092A (zh) * 2014-11-24 2016-05-25 北京凯因科技股份有限公司 含有白介素15的防治hpv感染的疫苗喷雾剂
CN109464661B (zh) * 2018-12-14 2022-05-10 中国科学院过程工程研究所 一种疫苗抗原组合物及其制备方法

Also Published As

Publication number Publication date
EP4380615A1 (en) 2024-06-12
WO2023014853A1 (en) 2023-02-09
US20230048144A1 (en) 2023-02-16
TW202313658A (zh) 2023-04-01

Similar Documents

Publication Publication Date Title
Epstein et al. Head and neck malignancies associated with HIV infection
RU2676083C2 (ru) Иммуногенные композиции, содержащие силикатированный вирус, и способы применения
CO2022011392A2 (es) Vacuna contra hpv
JP7239910B2 (ja) 治療剤、ならびに腫瘍および／またはがんの治療のための薬物のためのその使用
US20200121745A1 (en) Compositions and methods for cancer therapy with dengue virus and dendritic cells
CA3082779A1 (en) Combination immunotherapies for treatment of cancer
JP2016508999A5 (es)
EP3565567A1 (en) Compositions and methods for therapy with dengue virus
AR126708A1 (es) Vacuna para el vph
JP2018522880A (ja) デングウイルス及び樹状細胞による併用療法のための組成物及び方法
US8343478B2 (en) Parapoxviruses in combination with other antiviral agents for the treatment of viral diseases
AR097881A1 (es) FORMULACIÓN INMUNOGÉNICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTÍGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSIÓN QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADYUVANTE, APTA PARA SU USO FARMACÉUTICO
Silveira et al. Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice
UY38933A (es) Vacuna de partículas tipo virus del chicunguña y métodos para su uso
Fallah et al. Features of pathobiology and clinical translation of approved treatments for Coronavirus Disease 2019
CN115925823A (zh) SARS-CoV-2编码蛋白来源的T细胞表位多肽FAFPFTIYSL及其应用
JPWO2022235663A5 (es)
Mukhim African Swine Fever Virus: A Review on Its Heterogeneity, Immunomodulatory Property and Its Extent of Virulence
CN102727523A (zh) 一种具有抗hiv潜伏作用的药物及其用途
Pourjabbar et al. Cell therapy based SARS-cov 2-2019 managements: A literature review
Fiorentini et al. HIV-1 matrix protein p17 modulates in vivo preactivated murine T-cell response and enhances the induction of systemic and mucosal immunity against intranasally co-administered antigens
AR120296A1 (es) Vacuna de partículas de virus de tipo chikungunya y sus métodos de uso
US20180000926A1 (en) Methods of inducing an immune response to hepatitis c virus
AR132886A1 (es) Composiciones adyuvantes en nanoemulsión para vacunas contra el papilomavirus humano
Ng Dissolving the Oncogenic Virus Orchestra–A Review on the Effectiveness and Efficacy of Picking “The Low Hanging Fruits” By Vaccination

Legal Events

Date Code Title Description
FA Abandonment or withdrawal